Pleasantville, NY, United States of America

Naxin Tu

This inventor holds 35 USPTO granted patents and 17 published patent applications, plus 6 CIPO patents and 21 EPO patents, primarily in Genetically Modified Mice. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2014-2026.

USPTO Granted Patents = 35 (Patent Applications = 17)

% Patents Active = 100.0

CIPO Patents = 6 (Patent Applications = 14)

EPO Patents = 21 (Patent Applications = 33)

Average Co-Inventor Count = 5.5

ph-index = 5

Forward Citations = 123(Granted Patents)

Company Filing History:

35 out of 1,477

Regeneron Pharmaceuticals, Inc.

patents

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Genetically Modified Mice

T Cell Receptors

Humanized Fc Receptors

Immunoglobulin Light Chain

Major Histocompatibility Complex

TCRB Repertoire

Humanized Immune System

Non-Human Animals

Fc Gamma Receptors

Heavy Chain Loci

Terminal Deoxynucleotidyltransferase

Low Affinity FCGR

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12672644 - MICE EXPRESSING HUMANIZED FC ALPHA RECEPTORS (2026-07-07),

2. 12582105 - GENETICALLY MODIFIED T CELL RECEPTOR MICE (2026-03-24),

3. 12433264 - Non-human animals having an engineered immunoglobulin lambda light chain locus (2025-10-07),

4. 12376573 - Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire (2025-08-05),

5. 12295354 - Non-human animals expressing exogenous terminal deoxynucleotidyltransferase (2025-05-13),

6. 12063915 - Humanized T cell co-receptor mice (2024-08-20),

7. 12036288 - Methods of using humanized FCγR mice to assay Fc regions (2024-07-16),

8. 11576984 - Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using (2023-02-14),

9. 11528895 - Genetically modified T cell receptor mice (2022-12-20),

10. 11503812 - Non-human animals having humanized Fc-gamma receptors (2022-11-22),

11. 11219195 - Genetically modified major histocompatibility complex mice (2022-01-11),

12. 11186848 - Non-human animals expressing humanized C1Q complex (2021-11-30),

13. 11020495 - Humanized low affinity FCγR mouse cells (2021-06-01),

14. 10986822 - Genetically modified major histocompatibility complex mice (2021-04-27),

15. 10980221 - Non-human animals expressing exogenous terminal deoxynucleotidyltransferase (2021-04-20),

Title: The Innovative Journey of Naxin Tu

Introduction: Naxin Tu, a visionary inventor based in Pleasantville, NY, has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Naxin Tu holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and innovative spirit.

Career Highlights: Throughout his illustrious career, Naxin Tu has been recognized for his pioneering work in developing cutting-edge solutions that have revolutionized various industries. His commitment to pushing the boundaries of innovation has led to the creation of products that have positively impacted society.

Collaborations: Naxin Tu has collaborated with leading research institutions, universities, and companies to further his inventions and bring them to market. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: In conclusion, Naxin Tu's passion for innovation, coupled with his dedication to creating solutions that address real-world challenges, has established him as a prominent figure in the world of inventors. His relentless pursuit of excellence continues to inspire future generations of inventors and innovators.